About ASCENTAGE PHARMA GROUP INTERNATIONAL
https://www.ascentage.cnAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
CEO
Dajun Yang
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 24, 2025
Full time employees 567
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $51
Target Low $45
Target Median $48
Target Consensus $48
Market Cap $2.59 B
52w High $48.45
52w Low $16.50
P/E -13.41
Volume 3.17K
Outstanding Shares 92.96M
About ASCENTAGE PHARMA GROUP INTERNATIONAL
https://www.ascentage.cnAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $233.7M ▲ | $766.03M ▲ | $-590.77M ▼ | -252.79% ▲ | $-1.73 ▲ | $-514.02M ▲ |
| Q4-2024 | $156.9M ▼ | $709.66M ▲ | $-568.43M ▼ | -362.28% ▼ | $-1.82 ▼ | $-528.45M ▼ |
| Q2-2024 | $823.75M ▲ | $620.7M ▲ | $163M ▲ | 19.79% ▲ | $0.56 ▲ | $229.59M ▲ |
| Q4-2023 | $79.28M ▼ | $598.96M ▲ | $-523.29M ▼ | -660.01% ▼ | $-1.8 ▲ | $-492.67M ▼ |
| Q2-2023 | $142.7M | $465.12M | $-402.35M | -281.96% | $-11.32 | $-250.94M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $1.66B ▲ | $3.05B ▲ | $2.37B ▲ | $666M ▲ |
| Q4-2024 | $1.24B ▲ | $2.62B ▼ | $2.34B ▲ | $264.19M ▼ |
| Q2-2024 | $1.1B ▲ | $3.11B ▲ | $2.33B ▼ | $766.4M ▲ |
| Q4-2023 | $1.07B ▼ | $2.5B ▼ | $2.43B ▲ | $60.42M ▼ |
| Q2-2023 | $1.58B | $2.92B | $2.32B | $589.89M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-1.18B ▼ | $0 ▼ | $0 ▲ | $0 ▲ | $0 | $0 ▼ |
| Q4-2024 | $-568.43M ▼ | $243.03M ▲ | $-230.76M ▼ | $-82.14M ▼ | $0 ▼ | $235.27M ▲ |
| Q2-2024 | $163M ▲ | $-354.39M ▲ | $-131.28M ▼ | $396.91M ▲ | $952.43M ▲ | $-370.92M ▼ |
| Q4-2023 | $-523.29M ▼ | $-357.61M ▲ | $86.7M ▲ | $-86.88M ▼ | $0 ▲ | $-369.75M ▲ |
| Q2-2023 | $-409.58M | $-368.46M | $-64.77M | $455.63M | $-307.59M | $-413.18M |
CEO
Dajun Yang
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 24, 2025
Full time employees 567
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $51
Target Low $45
Target Median $48
Target Consensus $48